Vad ca a continuat treaba juliana. In primul rand bine v-am regasit, La Multi ANi si sper ca totul e bine la toata lumea. Incepem un nou an, sper cu cat mai multe stiri bune si aparitii de medicamente miraculoase.
Pentru cine se intreba ce mai fac, sunt pe aici nu va faceti griji ca trec de cel putin 10 ori pe zi, insa eu prea multe neclaritati nu prea mai am, tot ce pot sa fac este sa mai ajut pe cineva cu sfaturi si o vorba buna.
http://archive.mail-...h/msg09068.html
Un articol despre acelasi medicament Adefovir, se pare cel mai eficace pentru moment:
"Adefovir Dipivoxil Produces Sustained Improvement in HBV over Long Term:
Presented at HEP DART
By Bonnie Darves
KOHALA COAST, HI -- December 29, 2005 -- Patients with chronic hepatitis B
(HBV) who continue taking adefovir dipivoxil (ADV) for up to 5 years
continue to see improvements in hepatic fibrosis, HBV DNA suppression and
alanine aminotransferase (ALT) levels, with few adverse effects.
The new data on ADV were presented here at the Frontiers in Drug Development
for Viral Hepatitis HEP DART 2005 meeting.
"At 5 years the durability of this [therapy] is still greater than 91%, and
efficacy increased over time in all patient populations and disease stages,"
said presenter Carol Brosgart, MD, Vice President of Public Health and
Policy for the drug's maker, Gilead Sciences, Foster City, California,
United States.
In his presentation, Dr. Brosgart discussed long-term data on ADV, the first
of a new class of nucleotide analogues of adenosine monophosphate.
The study evaluated the drug in two primary groups of patients. The first
group included 123 treatment-naïve chronic HBV patients with compensated
liver function, and the second comprised three cohorts of nearly 500
lamivudine-resistant HBV patients -- those who were wait-listed for liver
transplantation, post-transplant patients, and those with HIV co-infection.
Efficacy at 5 years was similar across all groups, Dr. Brosgart noted, with
approximately 70% achieving increasingly improved fibrosis as measured by a
reduction of 1 point or greater on the Ishak Fibrosis scale. ALT
normalization occurred in 69% of the treatment-naïve patients at 5 years and
67%.
In HBV/HIV coinfected patients, ALT normalization occurred in 84% at 5
years, and the median log-10 reduction in serum HBV DNA was 6.4, Dr.
Brosgart noted. "The magnitude of those reductions continued to increase
with treatment duration," she said.
The drug was well tolerated in all patient groups. Less than 3% of patients
developed confirmed serum creatinine increases of 0.5 mg/dL over baseline.
No ADV mutations were seen and virologic breakthrough occurred in one
patient.
"We now have nearly 400,000 patient years of [ADV] treatment data to date,
and it is clear that it is well tolerated, with no [tolerability] change
with extended dosing," she said, adding that ADV's activity can be enhanced
over time.
She cited convenient dosing schedules, a single daily 10 mg dose that does
not require timing with food intake, as an additional advantage of the drug
over earlier HBV therapies."
Pacientii cu hepatita cronica B care au continuat administrarea Adefovirului pana la 5 ani au continuat sa inregistreze imbunatatiri ale fibrozei !!!! supresia HBV DNA (niveluri nedetectabile) si a nivelului transaminazelor, cu putine efecte adverse.
Dupa 5 ani de continuitate, durabilitatatea este mai mare de 91% si o eficacitate crescatoare in timp pentru toti pacientii, indiferent de populatie sau de stadiul bolii.
Studiul pentru evaluarea acestui medicament a urmarit 2 grupuri de pacienti. Primul grup cuprindea 123 de pacienti care nu au urmat anterior tratament cu functii hepatice compensate, si al doilea grup cuprinde 3 sub-grupuri aproape 500 de pacienti cu rezistenta la lamivudina (adica 1. pacienti pe lista de transplant hepatic, 2. pacienti post transplant, 3. cei cu coinfectie cu HIV)
Eficacitatea dupa 5 ani a fost similara in toate grupurile cu aprox. 70% imbunatatire a fibrozei masurata prin reducerea cu 1 pct sau mai mult a scorului Ishak, normalizarea a transaminazelor in 69% din cazuri pt pacientii naivi.
Pt pacientii cu coinfectie HBV-HIV normalizarea transam. a avut loc in 84% din cazuri si o reducere a HBV DNA de 6.4 log 10.
Asadar vesti bune cu acest tratament. Asteptam sa devina standard si la noi in tara.
Contact
Facebook
Twitter
RSS
Scris 23 December 2005 - 09:46 AM
Imi e mai frica de asta decat de hepatita.
